Print

European Medicines Agency Validates Gilead Sciences, Inc. (GILD)'s Marketing Application for Elvitegravir for Treatment of HIV Infection  
6/19/2012 10:43:20 AM

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA). Gilead submitted the MAA on May 22, 2012. Review of the MAA will be conducted under the centralized licensing procedure, which, when finalized, provides one marketing authorization in all 27 member states of the European Union (EU).
//-->